Conducting a supportive oncology clinical trial during the COVID-19 pandemic: challenges and strategies.

Autor: Deng J; University of Pennsylvania, Philadelphia, PA, USA. jiedeng@nursing.upenn.edu., Lukens JN; University of Pennsylvania, Philadelphia, PA, USA., Cohn JC; University of Pennsylvania, Philadelphia, PA, USA., McMenamin E; University of Pennsylvania, Philadelphia, PA, USA., Murphy B; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Spinelli BA; Thomas Jefferson University, Philadelphia, PA, USA., Murphy N; University of Pennsylvania, Philadelphia, PA, USA., Steinmetz AK; University of Pennsylvania, Philadelphia, PA, USA., Landriau MA; University of Pennsylvania, Philadelphia, PA, USA., Lin A; University of Pennsylvania, Philadelphia, PA, USA.
Jazyk: angličtina
Zdroj: Trials [Trials] 2022 Nov 08; Vol. 23 (1), pp. 927. Date of Electronic Publication: 2022 Nov 08.
DOI: 10.1186/s13063-022-06804-w
Abstrakt: The coronavirus disease 2019 (COVID-19) pandemic resulted in severe interruptions to clinical research worldwide. This global public health crisis required investigators and researchers to rapidly develop and implement new strategies and solutions to mitigate its negative impact on the progress of clinical trials. In this paper, we describe the challenges, strategies, and lessons learned regarding the continuation of a supportive oncology clinical trial during the pandemic. We hope to provide insight into the implementation of clinical trials during a public health emergency to be better prepared for future instances.Trial registration: ClinicalTrials.gov, a service of the US National Institute of Health (NCT03030859). Registered on 22 January 2017.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje